Literature DB >> 6112078

Biopterin in human brain and urine from controls and parkinsonian patients: application of a new radioimmunoassay.

T Nagatsu, T Yamaguchi, T Kato, T Sugimoto, S Matsuura, M Akino, I Nagatsu, R Iizuka, H Narabayashi.   

Abstract

Total biopterin concentrations in the post-mortem human brain (caudate nucleus) and in the urine of controls and parkinsonian patients were measured by a newly developed radioimmunoassay. There was good correlation between the total biopterin level and tyrosine hydroxylase activity in the human brain. Biopterin concentrations in the caudate nucleus were greatly reduced in parkinsonian patients. In contrast, the reduction of urinary biopterin in parkinsonian patients was slight and not statistically significant, as compared with normal controls.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112078     DOI: 10.1016/0009-8981(81)90316-8

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  17 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

2.  Isolation of a full-length cDNA clone for human GTP cyclohydrolase I type 1 from pheochromocytoma.

Authors:  T Nomura; M Ohtsuki; S Matsui; C Sumi-Ichinose; H Nomura; Y Hagino; K Iwase; H Ichinose; K Fujita; T Nagatsu
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  Sepiapterin reductase expression is increased in Parkinson's disease brain tissue.

Authors:  Jennifer E Tobin; Jing Cui; Jemma B Wilk; Jeanne C Latourelle; Jason M Laramie; Ann C McKee; Mark Guttman; Samer Karamohamed; Anita L DeStefano; Richard H Myers
Journal:  Brain Res       Date:  2007-01-08       Impact factor: 3.252

4.  Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.

Authors:  R J Mandel; K G Rendahl; S K Spratt; R O Snyder; L K Cohen; S E Leff
Journal:  J Neurosci       Date:  1998-06-01       Impact factor: 6.167

5.  Reduced levels of nitric oxide metabolites in cerebrospinal fluid are associated with equine protozoal myeloencephalitis.

Authors:  Chinedu J Njoku; William J A Saville; Stephen M Reed; Michael J Oglesbee; Päivi J Rajala-Schultz; Roger W Stich
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

6.  Effects of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on the dopaminergic and cholinergic receptors as evaluated by positron emission tomography in the Rhesus monkey.

Authors:  Y Tani; T Ishihara; T Kanai; T Ohno; J Andersson; A Lilja; G Antoni; K J Fasth; P Bjurling; G Westerberg
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 7.  Gene therapy: a viable therapeutic strategy for Parkinson's disease?

Authors:  Alexander L Berry; Thomas Foltynie
Journal:  J Neurol       Date:  2010-10-21       Impact factor: 4.849

Review 8.  Is NADH effective in the treatment of Parkinson's disease?

Authors:  R H Swerdlow
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

9.  Immunocytochemical localization of GTP cyclohydrolase I in the brain, adrenal gland, and liver of mice.

Authors:  I Nagatsu; H Ichinose; M Sakai; K Titani; M Suzuki; T Nagatsu
Journal:  J Neural Transm Gen Sect       Date:  1995

10.  Iron, a new aid in the treatment of Parkinson patients.

Authors:  W Birkmayer; J G Birkmayer
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.